|Bid||2.00 x 800|
|Ask||0.00 x 3100|
|Day's Range||2.0500 - 2.2200|
|52 Week Range||1.4000 - 11.6900|
|Beta (3Y Monthly)||1.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
Teva's (TEVA) shares rally as it enters into an agreement to settle all patent litigation related to its abbreviated new drug application for Neos Therapeutics' ADHD drug, Cotempla XR-ODT.
Shares of generic-drug maker Teva Pharmaceuticals Industries Ltd. rose about 5% Wednesday on news of a settlement and licensing agreement with Neos Therapeutics Inc. to resolve a patent dispute about a treatment for attention deficit disorders, or ADHD.
The settlement includes a licensing deal that will allow Teva to market a generic version of Cotempla beginning mid-2026.
Shares of generic drug maker Teva Pharmaceuticals Industries Ltd. rose 2.5% in premarket trade Wednesday, after Neos Therapeutics Inc. said it has entered a confidential settlement and licensing agreement with Teva to resolve patent litigation relating to a treatment for ADHD. Under the terms of the deal, Neos has granted Teva the right to make and market its generic version of Cotempla XR-ODT under a TEVA Abbreviated New Drug Application starting July 1, 2026, or earlier under certain circumstances. "We are pleased to have reached this settlement and will continue to defend our innovative medicines against any challenge," said Jerry McLaughlin, Chief Executive Officer of Neos Therapeutics, in a statement. Neos shares were not active premarket, but have fallen 84.5% in 2018. Teva shares have fallen 23% in 2018, while the S&P 500 has fallen 12.1%.
DALLAS and FORT WORTH, Texas, Dec. 26, 2018 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing.
Neos Therapeutics, Inc. (NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing, and commercializing innovative modified-release products using its proprietary microparticle, drug delivery technology, today announced that it completed a strategic assessment of its commercial business and is realigning its commercial organization for its attention deficit hyperactivity disorder (ADHD) products Adzenys XR-ODT®, Cotempla XR-ODT® and Adzenys-ER™ in order to accelerate its path to profitability.
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as its President and Chief Executive Officer succeeding Bill Enright, current President and Chief Executive Officer, effective November 30. “Vipin was chosen in a very competitive selection process and we are very excited to have him join Altimmune as President and CEO,” said Mitch Sayare, Chairman of the Board of Altimmune. “His extensive experience and success in building, managing, and financing private and public biotech companies makes him an extraordinary fit for Altimmune.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -7.50% and -15.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Grand Prairie, Texas-based company said it had a loss of 43 cents per share. The pharmaceutical company posted revenue of $12.5 million in the period. The company's shares closed at $2.58. A year ago, ...
Company to host conference call today at 8:30am ET DALLAS and FORT WORTH, Texas, Nov. 09, 2018 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical.
DALLAS and FORT WORTH, Texas, Nov. 06, 2018 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and.
Neos Therapeutics, Inc. (NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative modified-release products using its proprietary microparticle, drug delivery technology, today announced that it has commenced an underwritten public offering of its common stock. In addition, Neos expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
DALLAS and FORT WORTH, Texas, , Nov. 02, 2018 -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will report third quarter 2018 financial results prior to the.
Johnson & Johnson’s (JNJ) neuroscience business’s revenue remained flat in the third quarter compared to the third quarter of 2017. The business’s net revenue totaled $4.58 billion in the first nine months of 2018 compared to $4.46 billion in the same period of the previous year, reflecting a ~2.6% YoY rise. In the third quarter, in the US and international markets, Johnson & Johnson’s neuroscience business generated revenues of $651.0 million and $839.0 million, respectively, compared to $647.0 million and $851.0 million, respectively, in the third quarter of 2017.
DALLAS and FORT WORTH, Texas, Oct. 24, 2018 -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will present new data for Adzenys XR-ODT (amphetamine).
Approximately 1.4 Million Patients in the U.S. with Neurological Diseases Battle Sialorrhea with Burdensome and Complex Treatment Options Development Strategy Leverages Neos’.
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -20.93% and -4.51%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?